Fig. 1. SUPT5H is highly expressed in breast cancer (A) Expression status of SUPT5H in different cancers and their respective normal tissues obtained from BioXpress database. Log2 fold change (Log2FC) between the mRNA expression in cancerous and adjacent tissues of greater than zero for SUPT5H is considered to be over-expression and less than zero to be under-expression. Abbreviations: Breast cancer [BRCA], Liver cancer [LIVCA], Lung squamous cell carcinoma [LUSC], Head and neck cancer [H&NC], Prostate cancer [PCa]. (B) CPTAC data from UALCAN indicated that expression of SUPT5H was significantly up-regulated in breast cancer tissues (n=125) compared to normal breast tissues (n=18), P<10^-7. (C) Based on CPTAC from UALCAN, the expression of SUPT5H in normal breast tissues and breast cancer tissue with different subclasses (D) The expression of SUPT5H protein in normal tissues and breast cancer tissues with different grades of tumor. Significant up-regulation was observed in stage 2 and stage 3 of breast cancers. (E) SUPT5H transcript profiling of two breast cancers in a cohort of 63 patients (51 ER+, 12 triple-negative), with increased expression in triple-negative according to E-MTAB-4993 dataset from KM-express database. (F) Expression status of SUPT5H in breast cancer subtype cell lines according to GSE48213 dataset from KM-express database. (G) Representative immunohistochemistry images of SUPT5H protein expression in breast cancer and normal tissues. Scale bar, 100 µm.